Correlation between progression of nonproliferative diabetic retinopathy and high level of glycated hemoglobin in patients with diabetes mellitus type II
P. A. Bezdetko, Y N. Ilyina, S. M. Ajaj
Kharkiv national medical university
Key words: glycosylated hemoglobin, diabetic retinopathy, correlation coefficient.
40 patients with nonproliferative diabetic retinopathy (DR) in diabetes mellitus type II and decompensated (after 7.5 %) level of glycosylated hemoglobin were observed within one year. The correlation between signs of DR and level of glycosylated hemoglobin were determined. Research included: static perimetry, optical coherent tomography, fluorescein angiography. As a result, significant correlation was established between the level of glycosylated hemoglobin and mean deviation MD (r=0,36; r=0,49), quantity of local defects in the visual field (r=0,35; r=0,47), thickness and volume of the central retina (r=0,34; r=0,49 and r=0,47; r=0,60), p<0,05 respectively in stage A and stage B of nonproliferative diabetic retinopathy (NPDR). NPDR was progressed from stage A to stage C within one year. Direct correlation was increased in 1.4 times during the year.
1.Dedov II, Shestakova MV. Diabetes mellitus. (Manual for doctors). M.: Medizdat; 2009: 151- 75, 282- 92.
2.Dedov II, Shestakova MV, Maksimova MA. Federal target programme diabetes mellitus. Moscow; 2002. 59 p.
3.Yermakova NA, Antsiferov MB, Klimova NV. Clinical value of early detection of diabetic retinopathy. M.: Medizdat; 2006. 47p.
4.Yefimov AS, Skrobonskaya NA. Clinic diabetology. 1st ed. K.: Zdorovie; 1998. 320 p.
5.Klyuyev GO. Ophthalmic complications of diabetes: diagnosis, treatment and prognosis. Zdorovie Ukrainy. 2008; 8: 50-1. Russian.
6.Dedov II, editor. Criteria of compensation of carbohydrate metabolism disorder and target of HbA1C in diabetes: Federal target programme «Diabetes» (Method. recommendation for doctors). M.: Medizdat; 2007. 37 p.
7.Lopach SN, Chubenko AV, Babich PN. Statistic methods in medical and biological researches with the use of Excel. K.: Morion; 2000. 320 p.
8.Ponomarchuk VS, Slobodyanik SB, Drozhenko VS. Application of phosphene electrostimulation in treatment of patients with optic nerve atrophy and amblyopia: methodological recommendation. Odessa: Astroprint; 1999. 14 p.
9.Glantz S. Primer of biostatistics. Danilova Yu, translator. Moscow: Praktika; 1999: 250- 84.
10.Nguyen Q. Correlation between hemoglobin A1C and per-sistent diabetic clinically significant macular edema. Baltimore, US; 2008. 119 p.
11.Diabetes Care. American Diabetes Association. Suppl. 1; 2008. 143 p.
12.Foad AB. The Value of HbA1c testing in diabetic patients. J Diabetes Complications. 2009; 6: 3-9.
13.Funatsu H, Yamashita H, Ohashi Y. Effect of rapid glycemic control on progression of diabetic retinopathy. Jpn J Ophthalmol. 2012; 36: 356- 67.
14.Henricsson M, Nilsson A, Groop L. Prevalence of diabetic retinopathy in relation to age at onset of the diabetes, treat-ment, duration and glycemic. Acta Ophthalmol Scand. 2006; 74: 523-7.
15.Ozmen B, Boyvada S. The relationship between self-moni-toring of blood glucose control and glycosylated haemoglobin in patients with type 2 diabetes with and without diabetic retinopathy. J Diabetes Complications. 2008; 17: 128-34.
16.Aiello L, Beetham W, Marios CB et al. Ruby laser photoco-agulation in treatment of proliferative diabetic retinopathy. Goldberg M, eds. Washington DC: USDHEW Pub. 1968; 1890: 437-63.
17.WHO/IDF Europe. Diabetes Care and Research in Europe / Diabetic Medicine. — the St. Vinsent Declaration. 1990. 7: 360.